SCHEMBL25315909

SCHEMBL25315909

O=C(N[C@@H]1[C@@H]2CN(C(=O)c3sccc3-n3cccc3)C[C@@H]21)c1cccc(-c2cn3ccccc3n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
RAB9A P51151 5/20 0.47
POLB P06746 4/20 0.47
LMNA P02545 3/20 0.47
GFER P55789 1/20 0.47
ALDH1A1 P00352 11/20 0.46
MAPT P10636 3/20 0.46
KMT2A Q03164 3/20 0.46
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
HPGD P15428 3/20 0.44
MAPK1 P28482 1/20 0.41
NPC1 O15118 3/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 2/20 0.40
GAA P10253 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27180290 1.00 KDM4E (0.47) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25878317 1.00 KDM4E (0.47) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25878144 0.86 KDM4E (0.57) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25883229 0.80 KDM4E (0.58) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25883305 0.77 KDM4E (0.47) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25878406 0.77 KDM4E (0.47) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25311688 0.77 KDM4E (0.54) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25311896 0.77 KDM4E (0.47) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL29484599 0.77 KDM4E (0.47) KDM4ESMN1; SMN2RAB9APOLBLMNA
SCHEMBL25878145 0.77 KDM4E (0.54) KDM4ESMN1; SMN2RAB9APOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2024-03-28 US disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LANCL2, CBS, LCP2 KDM4E 2757/4885SMN1; SMN2 3536/4885RAB9A 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.